Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
8
Recruiting, any sponsor type, condition "eosinophilic esophagitis"
By trial status
The same filters, counted in each status. Pick one to switch.
8 trials
Showing 1 to 8, recently updated first.
- A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).Pivotal-lookingRecruiting
Eupraxia Pharmaceuticals Inc.Industry
NCT05608681 · 117 participants (planned) · Start Mar 31, 2023 · Primary completion Dec 2026
Drug: EP-104GI · For: Eosinophilic Esophagitis
Sites: Sydney, Australia; Brisbane, Australia; Maroochydore, Australia · 33 sites in all
University of North Carolina, Chapel HillAcademic, hospital or other
NCT07588568 · 52 participants (planned) · Start Sep 30, 2026 · Primary completion Feb 2030
Drug: Upadacitinib 30mg Dose · For: EoE; Eosinophilic Esophagitis; Eosinophilic Esophagitis (EoE)
Sites: Chapel Hill, North Carolina; Durham, North Carolina
- A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic EsophagitisPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07112378 · 20 participants (planned) · Start Nov 10, 2025 · Primary completion Jun 19, 2028
Drug: dupilumab · For: Eosinophilic Esophagitis (EoE)
Sites: Phoenix, Arizona; San Francisco, California; Aurora, Colorado · 13 sites in all
SanofiSanofi (SNY)
NCT06695897 · 150 participants (planned) · Start May 28, 2025 · Primary completion Jun 1, 2027
Drug: Dupilumab · For: Eosinophilic Esophagitis
Sites: Aschaffenburg, Germany; Augsburg, Germany; Dachau, Germany · 15 sites in all
Children's Hospital Medical Center, CincinnatiAcademic, hospital or other
NCT05485155 · 15 participants (planned) · Start May 15, 2025 · Primary completion Oct 2026
Drug: Alpha-proteinase inhibitor · For: Eosinophilic Esophagitis
Sites: Bethesda, Maryland; Cincinnati, Ohio
- Dupilumab Therapy for EGIDsRecruiting
Children's Hospital of Fudan UniversityAcademic, hospital or other
NCT07257835 · 20 participants (planned) · Start Jan 1, 2025 · Primary completion Jan 1, 2027
Drug: Dupilumab - Standard Dose · For: Eosinophilic Gastrointestinal Disorders (EGIDs)
Sites: Shanghai, China
- EDN and Eosinophilic EsophagitisRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06387030 · 60 participants (planned) · Start Apr 19, 2024 · Primary completion Apr 2026
Drug: Blood sampling; Esophageal biopsies and 3 more · For: Eosinophilic Esophagitis
Sites: Paris, France
- Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoERecruiting
University of Colorado, DenverAcademic, hospital or other
NCT06705387 · 72 participants (planned) · Start Dec 23, 2024 · Primary completion Sep 2026
Drug: Dupilumab; Fluticasone · For: Eosinophilic Esophagitis
Sites: Aurora, Colorado
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.